AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9007598 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime/metronidazole combination
Number of subjects: 94
Study 1645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 350 mg/m2
Number of subjects: 26
Study 1645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 370 mg/m2
Number of subjects: 26
Study 1645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (dose range 330-370 mg/m2)
Number of subjects: 26
Study 1645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (dose > 300 mg/m2)
Number of subjects: 26
Study 1645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 26
Study 7016157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misonidazole at a dose of 3 g/m2 preceding each of 4 weekly radiation doses
Number of subjects: 55
Study 7016157 — intervention group
Group type: COMPARATOR
Intervention: Control radiation group 1
Number of subjects: 55
Study 7016157 — intervention group
Group type: COMPARATOR
Intervention: Control radiation group 2
Number of subjects: 55
Study 31547939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium bicarbonate solution
Number of subjects: 916
Study 31547939 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline solution
Number of subjects: 916
Study 31547939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 916
Study 31547939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 30615068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern rich in calcium, potassium, and protein
Number of subjects: 401
Study 28017489 — intervention group
Group type: EXPERIMENTAL
Intervention: Video telehealth intervention
Number of subjects: 0
Study 28017489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28017489 — intervention group
Group type: EXPERIMENTAL
Intervention: Other intervention group
Number of subjects: 0
Study 25709422 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of prevalent delirium in general medical wards
Number of subjects: 116
Study 25709422 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of prevalent delirium in geriatric medical wards
Number of subjects: 116
Study 25161293 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14
Study 25161293 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with functional movement disorders
Number of subjects: 14
Study 22247354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 50 mg
Number of subjects: 152
Study 22247354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 200 mg
Number of subjects: 152
Study 22247354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 500 mg
Number of subjects: 152
Study 22247354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 22247354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) (combined groups)
Number of subjects: 152
Study 20085455 — intervention group
Group type: EXPERIMENTAL
Intervention: FKD peptide and p(S/T)F antibody
Number of subjects: 1200000
Study 20085455 — intervention group
Group type: EXPERIMENTAL
Intervention: Plk1 deletion mutant
Number of subjects: 1200000
Study 20085455 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length active-mutant Plk1
Number of subjects: 1200000
Study 16857266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazadone alone (MED)
Number of subjects: 681
Study 16857266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy alone (CBASP)
Number of subjects: 681
Study 16857266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (COMB)
Number of subjects: 681
Study 16857266 — intervention group
Group type: COMPARATOR
Intervention: Medication side-effects
Number of subjects: 681
Study 16857266 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic alliance scores
Number of subjects: 681
Study 16246781 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclidine 0.016%
Number of subjects: 30
Study 16246781 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclidine 0.032%
Number of subjects: 30
Study 16246781 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 12170039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 30
Study 12170039 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 30
Study 10502578 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser slit lamp
Number of subjects: 62
Study 10502578 — intervention group
Group type: COMPARATOR
Intervention: LOCS III
Number of subjects: 62
Study 8786596 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (amethocaine 1%)
Number of subjects: 60
Study 8786596 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (oxybuprocaine 0.4%)
Number of subjects: 60
Study 8786596 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (lignocaine 4%)
Number of subjects: 60
Study 8786596 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (amethocaine 1%)
Number of subjects: 60
Study 8786596 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (oxybuprocaine 0.4%)
Number of subjects: 60
Study 8786596 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (lignocaine 4%)
Number of subjects: 60
Study 3177196 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 42
Study 3177196 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 42
Study 3177196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Metoprolol + Nifedipine)
Number of subjects: 42
Study 31680502 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 120
Study 31680502 — intervention group
Group type: COMPARATOR
Intervention: MDL
Number of subjects: 120
Study 31680502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study 30638411 — intervention group
Group type: EXPERIMENTAL
Intervention: Raft-forming chewable tablets containing Nizatidine
Number of subjects: 0
Study 30638411 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulations using sodium alginate, calcium carbonate, and sodium bicarbonate
Number of subjects: 0
Study 30638411 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct compression technique and wet granulation technique
Number of subjects: 0
Study 30638411 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Ray evaluation of raft
Number of subjects: 0
Study 28296717 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed AWA (with gamma irradiation and decellularization)
Number of subjects: 6
Study 28296717 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed AWA (fresh, unprocessed)
Number of subjects: 6
Study 26026350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (25 mg/kg)
Number of subjects: 40
Study 26026350 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (0.2 mg/kg)
Number of subjects: 40
Study 26026350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone-Meloxicam (25 mg/kg and 0.2 mg/kg, respectively)
Number of subjects: 40
Study 26026350 — intervention group
Group type: COMPARATOR
Intervention: Control (physiological saline)
Number of subjects: 40
Study 22939006 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 18
Study 22939006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21236452 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ED(95) of rocuronium (0.3 mg/kg)
Number of subjects: 80
Study 21236452 — intervention group
Group type: COMPARATOR
Intervention: 2 ED(95) of rocuronium
Number of subjects: 80
Study 18320301 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 27
Study 18320301 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 27
Study 21980939 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding (observational analysis)
Number of subjects: 13889
Study 21980939 — intervention group
Group type: COMPARATOR
Intervention: Randomised experimental group
Number of subjects: 13889
Study 16191718 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (skills training and reinforcement)
Number of subjects: 53
Study 16191718 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (initial skills training followed by advice)
Number of subjects: 53
Study 11827684 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urotensin II (hUII) infusion at doses of 100 and 300 pmol min(‐1)
Number of subjects: 15
Study 11827684 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 15
Study 11827684 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urotensin II (hUII) infusion with nitric oxide clamp
Number of subjects: 15
Study 11827684 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of hUII (3‐300 pmol min(‐1))
Number of subjects: 15
Study 11827684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall systemic hemodynamics
Number of subjects: 15
Study 9881390 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting filter (group L, n = 20)
Number of subjects: 40
Study 9881390 — intervention group
Group type: COMPARATOR
Intervention: No leucocyte filter (group C, n = 20)
Number of subjects: 40
Study 9881390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L and C)
Number of subjects: 40
Study 7979954 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan at a dose of 0.1 mg/kg
Number of subjects: 67
Study 7979954 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan at a high dose (1.0 mg/kg or 2.0 mg/kg)
Number of subjects: 67
Study 7979954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 67
Study 7979954 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including PGG-glucan and placebo)
Number of subjects: 67
Study 3377942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl i.v. at 100 micrograms h‐1
Number of subjects: 45
Study 3377942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl i.v. at 125 micrograms h‐1
Number of subjects: 45
Study 3377942 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS-fentanyl)
Number of subjects: 45
Study 3377942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11686263 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information from an adult
Number of subjects: 0
Study 11686263 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information from a teacher or peer
Number of subjects: 0
Study 11686263 — intervention group
Group type: COMPARATOR
Intervention: Video information
Number of subjects: 0
Study 11686263 — intervention group
Group type: COMPARATOR
Intervention: No information given
Number of subjects: 0
Study 30882730 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 0
Study 30882730 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 0
Study 29630034 — intervention group
Group type: EXPERIMENTAL
Intervention: IV DEX 2.0 μg/kg
Number of subjects: 72
Study 29630034 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline (control)
Number of subjects: 72
Study 25896582 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent Video Games (VVGs)
Number of subjects: 0
Study 25896582 — intervention group
Group type: COMPARATOR
Intervention: Non-violent Video Games
Number of subjects: 0
Study 25252480 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus supplementation
Number of subjects: 40
Study 25252480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium and phosphorus supplementation)
Number of subjects: 40
Study 22357989 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC score of 1-100
Number of subjects: 958
Study 22357989 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC score of 101-1000
Number of subjects: 958
Study 22357989 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC score of more than 1000
Number of subjects: 958
Study 20558553 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 66
Study 20558553 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 66
Study 16494935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with Panavia F
Number of subjects: 16
Study 16494935 — intervention group
Group type: COMPARATOR
Intervention: Panavia F
Number of subjects: 16
Study 16494935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained seating pressure for 3 minutes
Number of subjects: 16
Study 16494935 — intervention group
Group type: COMPARATOR
Intervention: Sustained seating pressure for 5 seconds
Number of subjects: 16
Study 14993489 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (10-150 microg) administered once a week or once every 2 weeks
Number of subjects: 1502
Study 14993489 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (i.v.)
Number of subjects: 1502
Study 14993489 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (s.c.)
Number of subjects: 1502
Study 14993489 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (for subjects with baseline haemoglobin < 11 g/dl)
Number of subjects: 1502
Study 11641677 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered misoprostol (25 microg)
Number of subjects: 330
Study 11641677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral plus vaginal misoprostol (25 microg orally, 25 microg vaginally)
Number of subjects: 330
Study 11641677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (25 microg)
Number of subjects: 330
Study 9695781 — intervention group
Group type: EXPERIMENTAL
Intervention: Live tularemia vaccine (LTV) immunization 15-20 days before surgery
Number of subjects: 194
Study 9695781 — intervention group
Group type: COMPARATOR
Intervention: Standard uterine extirpation or with adnexa (control group)
Number of subjects: 194
Study 7723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex diet including proteins
Number of subjects: 932
Study 7723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulation agents
Number of subjects: 932
Study 7723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation
Number of subjects: 932
Study 2723257 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational movie on AIDS
Number of subjects: 0
Study 2723257 — intervention group
Group type: COMPARATOR
Intervention: Educational movie on first aid
Number of subjects: 0
Study 30309389 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ912 800 mg bid for 12 weeks
Number of subjects: 120
Study 30309389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28809743 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir (100 mg twice daily) + Daclatasvir (60 mg once daily) for 24 weeks
Number of subjects: 49
Study 26298715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255
Study 26298715 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroid therapy
Number of subjects: 255
Study 23121459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-reversible sustained-release green tea catechin gel
Number of subjects: 30
Study 23121459 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 21515474 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of dexmedetomidine at 0.2 µg·kg(‐1)·h(‐1)
Number of subjects: 40
Study 21515474 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study 18435868 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (types 6/11/16/18) L1 virus‐like‐particle vaccine
Number of subjects: 72
Study 16950199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 0
Study 16950199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 0
Study 16950199 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (both doses)
Number of subjects: 0
Study 16950199 — intervention group
Group type: COMPARATOR
Intervention: Aspirin cessation
Number of subjects: 0
Study 16950199 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (all dosing regimes)
Number of subjects: 0
Study 12969017 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection (no treatment prior to end of follow-up)
Number of subjects: 47
Study 10530493 — intervention group
Group type: EXPERIMENTAL
Intervention: AMT group (amoxycillin + metronidazole + tagamet)
Number of subjects: 96
Study 10530493 — intervention group
Group type: COMPARATOR
Intervention: OA group (omeprazole + amoxycillin)
Number of subjects: 96
Study 8684767 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcolposcopy before excisional treatment
Number of subjects: 330
Study 8684767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no microcolposcopy)
Number of subjects: 330
Study 1853617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment (250 mg daily) for 3 months starting from the seventh postoperative day
Number of subjects: 144
Study 1853617 — intervention group
Group type: COMPARATOR
Intervention: No ASA treatment (control group)
Number of subjects: 144
Study 1853617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 144
Study 6603042 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole, 2 tabs twice a day for 14 days
Number of subjects: 53
Study 6603042 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim, 250 mg twice a day for 14 days
Number of subjects: 53
Study 31842577 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program with ADT
Number of subjects: 0
Study 31842577 — intervention group
Group type: COMPARATOR
Intervention: Control group (ADT without exercise training)
Number of subjects: 0
Study 28414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 60
Study 28414522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 60
Study 28414522 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 60
Study 27158001 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging at 6 months (group A)
Number of subjects: 30
Study 27158001 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging at 9 months (group B)
Number of subjects: 30
Study 27158001 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging at 12 months (group C)
Number of subjects: 30
Study 27158001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of uncovered struts ratio <30%
Number of subjects: 30
Study 24552391 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study 24552391 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 22619082 — intervention group
Group type: EXPERIMENTAL
Intervention: DAFNE structured education program
Number of subjects: 639
Study 19639919 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkell film
Number of subjects: 0
Study 19639919 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating silk
Number of subjects: 0
Study 19639919 — intervention group
Group type: COMPARATOR
Intervention: Articulating paper
Number of subjects: 0
Study 19639919 — intervention group
Group type: COMPARATOR
Intervention: T‐Scan foil
Number of subjects: 0
Study 17222649 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg zinc
Number of subjects: 3640
Study 17222649 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 3640
Study 15583956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg budipine (t.i.d.)
Number of subjects: 51
Study 15583956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12485319 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 19
Study 12485319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10066843 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA treatment
Number of subjects: 450
Study 10066843 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 450
Study 10066843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (rtPA and placebo)
Number of subjects: 450
Study 7733031 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw potato starch (54% type II RS)
Number of subjects: 15
Study 7733031 — intervention group
Group type: COMPARATOR
Intervention: Pregelatinized starch (0% RS)
Number of subjects: 15
Study 2292534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg bd orally for 10 days
Number of subjects: 96
Study 2292534 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g daily im for 10 days
Number of subjects: 96
Study 6789356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (three doses)
Number of subjects: 0
Study 29741201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation (FPP®) 9g/day
Number of subjects: 30
Study 29741201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27105646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention package
Number of subjects: 462
Study 27105646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 462
Study 25492830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg/d, increased to 10 mg if BP control not achieved at 4 weeks)
Number of subjects: 80
Study 25492830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 80
Study 22571202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy (10 mg per day for the first 3 months, increased to 15 mg if tolerated)
Number of subjects: 614